Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
MBRX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

3.62

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-92.83

EPS This/Next Y

10.75

Price

2.41

Target Price

21

Analyst Recom

1

Performance Q

-38.21

Upside

-60,674.7%

Beta

1.73

Ticker: MBRX



16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09MBRX1.96N/AN/A0
2026-03-10MBRX1.96N/AN/A0
2026-03-11MBRX2.03N/AN/A0
2026-03-12MBRX2.02N/AN/A0
2026-03-13MBRX2.05N/AN/A0
2026-03-17MBRX2.12N/AN/A0
2026-03-18MBRX2.08N/AN/A0
2026-03-20MBRX2.04N/AN/A0
2026-03-25MBRX2.49N/AN/A0
2026-03-26MBRX2.41N/AN/A0
2026-03-27MBRX2.41N/AN/A0
2026-03-30MBRX2.21N/AN/A0
2026-03-31MBRX2.28N/AN/A0
2026-04-01MBRX2.2N/AN/A0
2026-04-06MBRX2.35N/AN/A0
2026-04-07MBRX2.44N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09MBRX1.98- 24.6-132.00
2026-03-10MBRX1.96- 24.2-132.00
2026-03-11MBRX2.01- 23.9-132.00
2026-03-12MBRX2.04- 24.2-132.00
2026-03-13MBRX2.10- 23.9-132.00
2026-03-17MBRX2.13- 23.8-132.00
2026-03-18MBRX2.06- 1.7-132.00
2026-03-19MBRX2.08- -5.0-132.00
2026-03-20MBRX2.05- -5.0-132.00
2026-03-23MBRX2.09- -4.1-132.00
2026-03-24MBRX2.26- -16.3-132.00
2026-03-25MBRX2.48- -16.3-132.00
2026-03-26MBRX2.40- -9.4-132.00
2026-03-27MBRX2.43- -6.0-132.00
2026-03-30MBRX2.23- -6.3-121.25
2026-03-31MBRX2.29- -11.5-121.25
2026-04-01MBRX2.22- -13.8-121.25
2026-04-02MBRX2.29- -13.9-121.25
2026-04-06MBRX2.33- -13.1-121.25
2026-04-07MBRX2.41- -16.7-121.25
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09MBRX0.003.1514.57
2026-03-10MBRX03.1514.57
2026-03-11MBRX03.156.31
2026-03-12MBRX03.156.31
2026-03-13MBRX03.156.31
2026-03-18MBRX01.706.31
2026-03-19MBRX01.706.31
2026-03-20MBRX01.706.31
2026-03-23MBRX01.566.31
2026-03-24MBRX01.566.31
2026-03-25MBRX01.563.62
2026-03-26MBRX01.563.62
2026-03-27MBRX01.563.62
2026-03-30MBRX01.563.62
2026-03-31MBRX01.563.62
2026-04-01MBRX01.563.62
2026-04-02MBRX01.563.62
2026-04-06MBRX01.563.62
2026-04-07MBRX01.563.62
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

-1.66

Avg. EPS Est. Next Quarter

-1.46

Insider Transactions

Institutional Transactions

1.56

Beta

1.73

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

4

Growth Score

19

Sentiment Score

26

Actual DrawDown %

99.8

Max Drawdown 5-Year %

-99.9

Target Price

21

P/E

Forward P/E

PEG

P/S

P/B

0.51

P/Free Cash Flow

EPS

-41.71

Average EPS Est. Cur. Y​

-121.25

EPS Next Y. (Est.)

-110.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.41

Return on Equity vs Sector %

-251.8

Return on Equity vs Industry %

-235.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-16.7
◆ MBRX Healthcare
$2.41
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
2/20
Pullback
11/25
Volume
11/15
Valuation
12/20
TP/AR
2/10
Options
0/10
RSI
48.5
Range 1M
84.9%
Sup Dist
5.8%
🚀
Momentum Growth
Ride accelerating trends
N/A
24 /100
WEAK
Momentum
1/25
Growth
20/30
Estimates
0/20
Inst/Vol
3/15
Options
0/10
EPS Yr
82.5%
EPS NY
22.8%
52W%
2.3%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +771.4% upside
Quality
2/30
Valuation
16/30
Growth
15/25
Stability
5/10
LT Trend
1/5
Upside
+771.4%
Quality
4
Click a card to see score breakdown Full Analysis →
Moleculin Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 17
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX

Latest News

—
Caricamento notizie per MBRX…
stock quote shares MBRX – Moleculin Biotech Inc Stock Price stock today
news today MBRX – Moleculin Biotech Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MBRX – Moleculin Biotech Inc yahoo finance google finance
stock history MBRX – Moleculin Biotech Inc invest stock market
stock prices MBRX premarket after hours
ticker MBRX fair value insiders trading